经血来源的间充质干细胞治疗早发性卵巢功能不全的进展

doi:10.12280/gjfckx.20220835

国际妇产科学杂志 ›› 2023, Vol. 50 ›› Issue (2): 161-164.doi: 10.12280/gjfckx.20220835

• 普通妇科疾病及相关研究:综述 • 上一篇下一篇

经血来源的间充质干细胞治疗早发性卵巢功能不全的进展

高悦文, 李长忠^△()

250000 济南，山东大学（高悦文，李长忠）；山东省立医院（高悦文，李长忠）；北京大学深圳医院妇产科（李长忠）

收稿日期:2022-10-14 出版日期:2023-04-15 发布日期:2023-04-24
通讯作者: 李长忠，E-mail：17854160053@163.com
^△审校者
基金资助:
山东大学荣祥再生医学基金(2019SDRX-21);济南市科技计划项目(202019161)

Research Progress of Menstrual Blood-Derived Mesenchymal Stem Cells in the Treatment of Premature Ovarian Insufficiency

GAO Yue-wen, LI Chang-zhong()

Shandong University, Jinan 250000, China (GAO Yue-wen, LI Chang-zhong); Shandong Provincial Hospital, Jinan 250000, China (GAO Yue-wen, LI Chang-zhong); Department of Obstetrics and Gynecology, Peking University Shenzhen Hospital, Shenzhen 518000, China (LI Chang-zhong)

Received:2022-10-14 Published:2023-04-15 Online:2023-04-24
Contact: LI Chang-zhong, E-mail: 17854160053@163.com

摘要/Abstract

摘要：

大多数早发性卵巢功能不全患者由于卵巢储备减少而表现为生育力降低，随着再生医学的发展，各种间充质干细胞越来越被考虑用于治疗早发性卵巢功能不全。其中，经血来源的间充质干细胞能够通过分化为靶向外源细胞、靶向损伤部位的归巢和植入、外泌体有效分泌一系列旁分泌细胞因子等机制改善卵巢功能，促进生育力的恢复，并具有来源丰富、非侵入性获取和免疫原性低等优点，被认为有希望作为治疗早发性卵巢功能不全的新方法，但经血来源的间充质干细胞移植在临床治疗中的应用尚不广泛。综述经血来源的间充质干细胞对卵巢功能的影响以及治疗早发性卵巢功能不全的可能机制，为进一步研究和临床治疗提供理论依据。

关键词: 干细胞, 间质干细胞, 原发性卵巢功能不全, 外泌体, 治疗

Abstract:

Most patients with premature ovarian insufficiency exhibit reduced fertility due to reduced ovarian reserve. With the development of regenerative medicine, various mesenchymal stem cells are increasingly being considered for the treatment of premature ovarian insufficiency. Among them, mesenchymal stem cells derived from menstrual blood can improve ovarian function and promote the recovery of fertility by differentiating into targeting exogenous cells, targeting the homing and implantation of injured sites, and effective secretion of a series of parasecretory cytokines by exosomes, with the advantages of rich sources, non-invasive acquisition and low immunogenicity. It is considered as a promising new method for the treatment of premature ovarian insufficiency, but the clinical application of menstrual blood-derived mesenchymal stem cell transplantation is not yet widely used. This paper reviews the effects of menstrual blood-derived mesenchymal stem cells on ovarian function and the possible mechanisms of treating premature ovarian insufficiency, providing theoretical basis for further research and clinical treatment.

Key words: Stem cells, Mesenchymal stem cells, Primary ovarian insufficiency, Exosomes, Therapy

高悦文, 李长忠. 经血来源的间充质干细胞治疗早发性卵巢功能不全的进展[J]. 国际妇产科学杂志, 2023, 50(2): 161-164.

GAO Yue-wen, LI Chang-zhong. Research Progress of Menstrual Blood-Derived Mesenchymal Stem Cells in the Treatment of Premature Ovarian Insufficiency[J]. Journal of International Obstetrics and Gynecology, 2023, 50(2): 161-164.

参考文献 21

[1]	McGlacken-Byrne SM, Conway GS. Premature ovarian insufficiency[J]. Best Pract Res Clin Obstet Gynaecol, 2022, 81:98-110. doi: 10.1016/j.bpobgyn.2021.09.011. doi: 10.1016/j.bpobgyn.2021.09.011
[2]	Shareghi-Oskoue O, Aghebati-Maleki L, Yousefi M. Transplantation of human umbilical cord mesenchymal stem cells to treat premature ovarian failure[J]. Stem Cell Res Ther, 2021, 12(1):454. doi: 10.1186/s13287-021-02529-w. doi: 10.1186/s13287-021-02529-w pmid: 34380572
[3]	Rahman R, Panay N. Diagnosis and management of premature ovarian insufficiency[J]. Best Pract Res Clin Endocrinol Metab, 2021, 35(6):101600. doi: 10.1016/j.beem.2021.101600. doi: 10.1016/j.beem.2021.101600
[4]	Meng X, Ichim TE, Zhong J, et al. Endometrial regenerative cells: a novel stem cell population[J]. J Transl Med, 2007, 5:57. doi: 10.1186/1479-5876-5-57. doi: 10.1186/1479-5876-5-57 pmid: 18005405
[5]	Chen L, Qu J, Cheng T, et al. Menstrual blood-derived stem cells: toward therapeutic mechanisms, novel strategies, and future perspectives in the treatment of diseases[J]. Stem Cell Res Ther, 2019, 10(1):406. doi: 10.1186/s13287-019-1503-7. doi: 10.1186/s13287-019-1503-7 pmid: 31864423
[6]	Zhang S, Zhu D, Li Z, et al. A stem cell-derived ovarian regenerative patch restores ovarian function and rescues fertility in rats with primary ovarian insufficiency[J]. Theranostics, 2021, 11(18):8894-8908. doi: 10.7150/thno.61690. doi: 10.7150/thno.61690 pmid: 34522217
[7]	Zhang S, Huang B, Su P, et al. Concentrated exosomes from menstrual blood-derived stromal cells improves ovarian activity in a rat model of premature ovarian insufficiency[J]. Stem Cell Res Ther, 2021, 12(1):178. doi: 10.1186/s13287-021-02255-3. doi: 10.1186/s13287-021-02255-3 pmid: 33712079
[8]	Yamchi NN, Rahbarghazi R, Bedate AM, et al. Menstrual blood CD146+ mesenchymal stem cells reduced fibrosis rate in the rat model of premature ovarian failure[J]. Cell Biochem Funct, 2021, 39(8):998-1008. doi: 10.1002/cbf.3669. doi: 10.1002/cbf.3669
[9]	Feng P, Li P, Tan J. Human Menstrual Blood-Derived Stromal Cells Promote Recovery of Premature Ovarian Insufficiency Via Regulating the ECM-Dependent FAK/AKT Signaling[J]. Stem Cell Rev Rep, 2019, 15(2):241-255. doi: 10.1007/s12015-018-9867-0. doi: 10.1007/s12015-018-9867-0 pmid: 30560467
[10]	Guo F, Xia T, Zhang Y, et al. Menstrual blood derived mesenchymal stem cells combined with Bushen Tiaochong recipe improved chemotherapy-induced premature ovarian failure in mice by inhibiting GADD45b expression in the cell cycle pathway[J]. Reprod Biol Endocrinol, 2019, 17(1):56. doi: 10.1186/s12958-019-0499-2. doi: 10.1186/s12958-019-0499-2
[11]	Hoang DM, Pham PT, Bach TQ, et al. Stem cell-based therapy for human diseases[J]. Signal Transduct Target Ther, 2022, 7(1):272. doi: 10.1038/s41392-022-01134-4. doi: 10.1038/s41392-022-01134-4
[12]	Chen L, Qu J, Xiang C. The multi-functional roles of menstrual blood-derived stem cells in regenerative medicine[J]. Stem Cell Res Ther, 2019, 10(1):1. doi: 10.1186/s13287-018-1105-9. doi: 10.1186/s13287-018-1105-9 pmid: 30606242
[13]	Sanchez-Mata A, Gonzalez-Muñoz E. Understanding menstrual blood-derived stromal/stem cells: Definition and properties. Are we rushing into their therapeutic applications?[J]. iScience, 2021, 24(12):103501. doi: 10.1016/j.isci.2021.103501. doi: 10.1016/j.isci.2021.103501
[14]	Liu T, Huang Y, Zhang J, et al. Transplantation of human menstrual blood stem cells to treat premature ovarian failure in mouse model[J]. Stem Cells Dev, 2014, 23(13):1548-1557. doi: 10.1089/scd.2013.0371. doi: 10.1089/scd.2013.0371 pmid: 24593672
[15]	Lai D, Guo Y, Zhang Q, et al. Differentiation of human menstrual blood-derived endometrial mesenchymal stem cells into oocyte-like cells[J]. Acta Biochim Biophys Sin(Shanghai), 2016, 48(11):998-1005. doi: 10.1093/abbs/gmw090. doi: 10.1093/abbs/gmw090
[16]	Manshadi MD, Navid S, Hoshino Y, et al. The effects of human menstrual blood stem cells-derived granulosa cells on ovarian follicle formation in a rat model of premature ovarian failure[J]. Microsc Res Tech, 2019, 82(6):635-642. doi: 10.1002/jemt.23120. doi: 10.1002/jemt.23120
[17]	Santos RA, Asensi KD, de Barros J, et al. Intrinsic Angiogenic Potential and Migration Capacity of Human Mesenchymal Stromal Cells Derived from Menstrual Blood and Bone Marrow[J]. Int J Mol Sci, 2020, 21(24):9563. doi: 10.3390/ijms21249563. doi: 10.3390/ijms21249563
[18]	Fu YX, Ji J, Shan F, et al. Human mesenchymal stem cell treatment of premature ovarian failure: new challenges and opportunities[J]. Stem Cell Res Ther, 2021, 12(1):161. doi: 10.1186/s13287-021-02212-0. doi: 10.1186/s13287-021-02212-0
[19]	Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes[J]. Science, 2020, 367(6478):eaau6977. doi: 10.1126/science.aau6977. doi: 10.1126/science.aau6977
[20]	Chen L, Qu J, Mei Q, et al. Small extracellular vesicles from menstrual blood-derived mesenchymal stem cells (MenSCs) as a novel therapeutic impetus in regenerative medicine[J]. Stem Cell Res Ther, 2021, 12(1):433. doi: 10.1186/s13287-021-02511-6. doi: 10.1186/s13287-021-02511-6 pmid: 34344458
[21]	Han Y, Yang J, Fang J, et al. The secretion profile of mesenchymal stem cells and potential applications in treating human diseases[J]. Signal Transduct Target Ther, 2022, 7(1):92. doi: 10.1038/s41392-022-00932-0. doi: 10.1038/s41392-022-00932-0

经血来源的间充质干细胞治疗早发性卵巢功能不全的进展

Research Progress of Menstrual Blood-Derived Mesenchymal Stem Cells in the Treatment of Premature Ovarian Insufficiency

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 21

相关文章 15

编辑推荐

Metrics

本文评价

[1]	杨洋, 马媛, 陈宥艺, 赵静, 马文娟. 重度子痫前期患者血清外泌体对人正常蜕膜免疫细胞功能的影响[J]. 国际妇产科学杂志, 2025, 52(2): 143-152.
[2]	陈晓娟, 张艳馨. 妊娠合并血友病A患者足月分娩一例[J]. 国际妇产科学杂志, 2025, 52(2): 158-160.
[3]	张昊晟, 魏芳. Nectin-4在妇科恶性肿瘤中的研究进展[J]. 国际妇产科学杂志, 2025, 52(2): 165-168.
[4]	林环宇, 邵小光, 路旭宏, 王秋月, 魏巍, 佟春艳. Web of Science核心数据库2004—2024年女性恶性肿瘤患者生育力保存的研究现状及热点[J]. 国际妇产科学杂志, 2025, 52(2): 180-186.
[5]	江爱美, 张信美. 腹壁子宫内膜异位症的治疗进展[J]. 国际妇产科学杂志, 2025, 52(2): 211-216.
[6]	王佳凝, 闫颖, 张晗, 褚梦圆, 张心怡. 沉默信息调节因子家族在女性生殖衰老中的机制研究进展[J]. 国际妇产科学杂志, 2025, 52(2): 222-227.
[7]	白耀俊, 王思瑶, 令菲菲, 张森淮, 李红丽, 刘畅. Trop-2及靶向Trop-2抗体偶联药物在妇科恶性肿瘤中的应用进展[J]. 国际妇产科学杂志, 2025, 52(1): 1-7.
[8]	侯春艳, 杜秀萍. 妊娠中晚期自发性子宫破裂二例[J]. 国际妇产科学杂志, 2025, 52(1): 110-113.
[9]	钟佩蕖, 招丽坚, 邹欣欣. 残角子宫妊娠行期待治疗至妊娠晚期一例[J]. 国际妇产科学杂志, 2025, 52(1): 114-116.
[10]	潘琪, 冯同富, 金晶, 吴莺, 杜欣. 腹腔镜切除成人腹膜后巨大成熟性畸胎瘤一例[J]. 国际妇产科学杂志, 2025, 52(1): 28-31.
[11]	贾炎峰, 吴珍珍, 王维红, 王玥元, 李娟. 原发性卵巢腺鳞癌一例[J]. 国际妇产科学杂志, 2025, 52(1): 32-36.
[12]	宋丽芳, 吴珍珍, 毛宝宏, 赵小丽, 刘青. 卵巢癌腹股沟淋巴结孤立转移一例[J]. 国际妇产科学杂志, 2025, 52(1): 37-41.
[13]	石百超, 王宇, 常惠, 卢凤娟, 关木馨, 余健楠, 吴效科. 中药及天然产物改善子宫内膜异位症的作用机制[J]. 国际妇产科学杂志, 2025, 52(1): 66-71.
[14]	李恒兵, 袁海宁, 张云洁, 张江琳, 郭子珍, 孙振高. 外泌体通过调控免疫微环境治疗慢性子宫内膜炎的研究进展[J]. 国际妇产科学杂志, 2025, 52(1): 72-78.
[15]	张野, 陈巧云, 赵佳怡, 陈璐, 刘建荣. 纳米微球在宫颈癌预防与治疗中的应用进展[J]. 国际妇产科学杂志, 2025, 52(1): 8-12.